Trametinib is a highly selective reversible allosteric inhibitor of MEK1/2 activity, and is an approved treatment for cancers with activation of the RAS/MAPK pathway e.g., lung adenocarcinoma (Berger et al., 2014). Here, MAP2K1 is linked to lung adenocarcinoma.